A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
← catalyst calendarNCT07004972 · readout in 481 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
24
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-04 | actual | When the study began enrolling |
| Primary completion | 2027-12-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
Intervention
- Drug: Mavacamten — also filed as BMS-986427
Primary outcome
what the primary-completion date above is the date OFIncidence of serious Treatment Emergent Adverse Events (TEAEs)
measured Up to Week 48
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed